Viridian Therapeutics VRDN has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 6 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Viridian Therapeutics, revealing an average target of $38.25, a high estimate of $61.00, and a low estimate of $27.00. Surpassing the previous average price target of $35.33, the current average has increased by 8.26%.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent analyst actions, we gain insights into how financial experts perceive Viridian Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Serge Belanger | Needham | Maintains | Buy | $38.00 | $38.00 |
| Julian Harrison | BTIG | Raises | Buy | $61.00 | $56.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $44.00 | $44.00 |
| Gregory Renza | RBC Capital | Raises | Outperform | $44.00 | $35.00 |
| Richard Law | Goldman Sachs | Raises | Buy | $31.00 | $25.00 |
| Serge Belanger | Needham | Raises | Buy | $38.00 | $30.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $27.00 | $27.00 |
| Julian Harrison | BTIG | Raises | Buy | $56.00 | $46.00 |
| Serge Belanger | Needham | Maintains | Buy | $30.00 | $30.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $35.00 | $35.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $27.00 | $27.00 |
| Leland Gershell | Oppenheimer | Lowers | Outperform | $28.00 | $31.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Viridian Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Viridian Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Viridian Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
To gain a panoramic view of Viridian Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Viridian Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Viridian Therapeutics: A Closer Look
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Viridian Therapeutics: Delving into Financials
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Viridian Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately 0.0%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Viridian Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -90268.06%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Viridian Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -18.25%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Viridian Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -10.69%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Viridian Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
